Paul R. Keller - Concepedia

Author

Paul R. Keller

Also Known As

F. Cavaillé, Keller, Paul, P . Keller, P Keller, P R Keller, P. KELLER, P. Keller, P. R. KELLER, P. R. Keller, P.R. Keller

Publications

Citations

H-Index

Concepts

All Affiliations

University of Tennessee at Knoxville University of Wisconsin–Madison Oak Ridge National Laboratory Pfizer (United States)University of Michigan

About

Paul R. Keller is an author at University of Tennessee at Knoxville specializing in natural sciences, chemistry, and engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Natural Sciences	19	25	1.8K
2	Engineering	15	16	573
3	Medicine	13	14	1.4K
4	Applied Physics	11	11	421
5	Health Sciences	1	1	21

Paul R. Keller

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts David W. Fry, Patricia J. Harvey, Paul R. Keller, Molecular Cancer Therapeutics	2004	1.2K
Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6 Peter L. Toogood, Patricia J. Harvey, Joseph T. Repine, Journal of Medicinal Chemistry Drug TargetExquisite SelectivityPharmacotherapyChemical BiologyPharmaceutical Chemistry	2005	498
Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor David W. Fry, Alexander J. Bridges, William A. Denny, Proceedings of the National Academy of Sciences Drug TargetCell GrowthChemical BiologyMedicinal ChemistrySignaling Pathway	1998	417
Assessment of Screening for Prostate Cancer Using the Digital Rectal Examination Gerald W. Chodak, Paul R. Keller, Harry W. Schoenberg The Journal of Urology	1989	179
Pyrido[2,3-<i>d</i>]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4 Scott N. VanderWel, Patricia J. Harvey, Dennis J. McNamara, Journal of Medicinal Chemistry Medicinal ChemistryDrug TargetExcellent SelectivityBiochemistryCyclin-dependent Kinase 4	2005	148
Cell Cycle and Biochemical Effects of PD 0183812 David W. Fry, David C. Bedford, Patricia H. Harvey, Journal of Biological Chemistry	2001	107
Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer Terence M. Williams, Athena R. Flecha, Paul R. Keller, Molecular Cancer Therapeutics Tumor BiologyPancreatic CancerPi3k SignalingMedicineMitogen-activated Protein Kinase	2012	77
Angle-resolved photoelectron spectroscopy of CCl4: The Cooper minimum in molecules Thomas A. Carlson, Manfred O. Krause, Frederick A. Grimm, The Journal of Chemical Physics EngineeringTheoretical Inorganic ChemistryChemistryElectronic Excited StateElectronic Structure	1982	69
Biochemical and antiproliferative properties of 4-[Ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor David W. Fry, James M. Nelson, Veronika Slintak, Biochemical Pharmacology Medicinal ChemistryBiochemistryMedicineNatural SciencesMechanism Of Action	1997	63
Angular distribution parameter as a function of photon energy for some mono- and diazabenzenes and its use for orbital assignment M. N. Piancaśtelli, Paul R. Keller, James W. Taylor Journal of the American Chemical Society Orbital AssignmentEngineeringAltmetric Attention ScoreOrganic ChemistryComputational Chemistry	1983	62

Page 1